|
US5178878A
(en)
|
1989-10-02 |
1993-01-12 |
Cima Labs, Inc. |
Effervescent dosage form with microparticles
|
|
US5558880A
(en)
|
1989-12-22 |
1996-09-24 |
Janssen Pharmaceutica Inc. |
Pharmaceutical and other dosage forms
|
|
US5464632C1
(en)
|
1991-07-22 |
2001-02-20 |
Prographarm Lab |
Rapidly disintegratable multiparticular tablet
|
|
GB9504201D0
(en)
|
1995-03-02 |
1995-04-19 |
Scherer Ltd R P |
Process for the preparation of a solid pharmaceutical dosage form
|
|
TW486370B
(en)
|
1996-12-25 |
2002-05-11 |
Yamanouchi Pharma Co Ltd |
Rapidly disintegrable pharmaceutical composition
|
|
US6024981A
(en)
|
1997-04-16 |
2000-02-15 |
Cima Labs Inc. |
Rapidly dissolving robust dosage form
|
|
US6433154B1
(en)
|
1997-06-12 |
2002-08-13 |
Bristol-Myers Squibb Company |
Functional receptor/kinase chimera in yeast cells
|
|
FR2766089B1
(fr)
|
1997-07-21 |
2000-06-02 |
Prographarm Lab |
Comprime multiparticulaire perfectionne a delitement rapide
|
|
PT1121103E
(pt)
|
1998-05-18 |
2007-02-28 |
Takeda Pharmaceutical |
Comprimidos de desintegração oral compreendendo um benzimidazole
|
|
US6350786B1
(en)
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
|
ES2307482T3
(es)
|
1999-02-10 |
2008-12-01 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas.
|
|
AU2001261625B2
(en)
|
2000-05-16 |
2006-04-06 |
Regents Of The University Of Minnesota |
High mass throughput particle generation using multiple nozzle spraying
|
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
|
EP1401503B1
(en)
|
2001-06-22 |
2007-05-09 |
Pfizer Products Inc. |
Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
|
|
CN1688291A
(zh)
|
2002-02-01 |
2005-10-26 |
辉瑞产品公司 |
含有固体药物分散体的即刻释放剂型
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
US20050112196A1
(en)
|
2003-10-07 |
2005-05-26 |
Jianbo Xie |
Rapidly disintegrating formulation
|
|
EP1753402B1
(en)
|
2004-05-28 |
2008-10-01 |
Pfizer Products Incorporated |
Pharmaceutical compositions with enhanced performance comprising a hpmca polymer
|
|
DE102005009240A1
(de)
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
|
|
GT200600315A
(es)
|
2005-07-20 |
2007-03-19 |
|
Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
|
|
GT200600316A
(es)
|
2005-07-20 |
2007-04-02 |
|
Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
|
|
WO2007089883A2
(en)
|
2006-01-31 |
2007-08-09 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
|
CA2637883C
(en)
|
2006-01-31 |
2015-07-07 |
Regents Of The University Of Minnesota |
Electrospray coating of objects
|
|
US9108217B2
(en)
|
2006-01-31 |
2015-08-18 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
|
EP1923053A1
(en)
*
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
|
WO2008055966A1
(en)
|
2006-11-09 |
2008-05-15 |
Abbott Gmbh & Co. Kg |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
EP1920767A1
(en)
|
2006-11-09 |
2008-05-14 |
Abbott GmbH & Co. KG |
Melt-processed imatinib dosage form
|
|
US9040816B2
(en)
|
2006-12-08 |
2015-05-26 |
Nanocopoeia, Inc. |
Methods and apparatus for forming photovoltaic cells using electrospray
|
|
EP2162120B1
(en)
|
2007-06-04 |
2016-05-04 |
Bend Research, Inc |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
|
TWI547282B
(zh)
|
2007-07-02 |
2016-09-01 |
愛戴爾製藥股份有限公司 |
樂命達之口服分解錠劑組合物
|
|
WO2009010837A2
(en)
|
2007-07-13 |
2009-01-22 |
Pfizer Products Inc. |
Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
|
|
US8992471B2
(en)
|
2007-11-05 |
2015-03-31 |
Nanocopoeia, Inc. |
Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity
|
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
EP2254556A2
(en)
|
2008-03-11 |
2010-12-01 |
Takeda Pharmaceutical Company Limited |
Orally-disintegrating solid preparation
|
|
GB0816365D0
(en)
*
|
2008-09-08 |
2008-10-15 |
Univ Belfast |
Polymeric material
|
|
CZ20098A3
(cs)
|
2009-01-13 |
2010-07-21 |
Zentiva, K.S. |
Lékové formy inhibitoru tyrosinových kináz
|
|
WO2011026080A1
(en)
|
2009-08-31 |
2011-03-03 |
Wilmington Pharmaceuticals, Llc |
Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain
|
|
EP3566697B1
(en)
|
2009-11-09 |
2024-09-11 |
Wyeth LLC |
Tablet formulations of neratinib maleate
|
|
JO3634B1
(ar)
|
2009-11-17 |
2020-08-27 |
Novartis Ag |
طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
|
|
RU2566716C2
(ru)
|
2010-06-09 |
2015-10-27 |
Эббви Бахамаз Лтд. |
Твердые дисперсии, содержащие ингибиторы киназ
|
|
JP6073788B2
(ja)
|
2010-09-14 |
2017-02-01 |
ナノロジカ アクティエボラーグ |
難水溶性医薬及び化粧品有効成分のための過飽和送達媒体
|
|
EP2665559B1
(en)
|
2011-01-19 |
2018-07-18 |
Washington University |
Electrohydrodynamic atomization nozzle emitting a liquid sheet
|
|
IN2011CH01887A
(cg-RX-API-DMAC7.html)
|
2011-06-02 |
2012-12-14 |
|
|
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
|
JP6062442B2
(ja)
|
2011-10-13 |
2017-01-18 |
ジェネンテック, インコーポレイテッド |
薬剤誘発性低酸症の治療
|
|
US9301957B2
(en)
|
2011-11-14 |
2016-04-05 |
Novartis Ag |
Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
|
|
HRP20210237T1
(hr)
|
2012-01-13 |
2021-03-19 |
Xspray Microparticles Ab |
Postupak za proizvodnju stabilnih, amorfnih hibridnih nanočestica koje sadrže barem jedan inhibitor proteinske kinaze i barem jedan polimerni sastojak koji stabilizira i tvori matricu
|
|
EP3181128B1
(en)
|
2012-01-13 |
2023-03-08 |
XSpray Pharma AB (publ) |
Nilotinib pharmaceuticalcomposition
|
|
US20130274342A1
(en)
|
2012-04-12 |
2013-10-17 |
Cerecor, Inc. |
Compositions and methods for treating cough
|
|
US10195150B2
(en)
|
2012-12-20 |
2019-02-05 |
Kashiv Pharma, Llc |
Orally disintegrating tablet formulation for enhanced bioavailability
|
|
TW201446286A
(zh)
|
2013-01-31 |
2014-12-16 |
Gilead Pharmasset Llc |
抗病毒化合物之固態分散調製劑
|
|
EP3102188A4
(en)
|
2014-02-05 |
2017-07-12 |
Merck Sharp & Dohme Corp. |
Novel disintegration systems for pharmaceutical dosage forms
|
|
MX2016010213A
(es)
|
2014-02-07 |
2017-04-13 |
Auspex Pharmaceuticals Inc |
Formulaciones farmaceuticas novedosas.
|
|
HU231013B1
(hu)
|
2014-05-26 |
2019-11-28 |
Egis Gyógyszergyár Zrt. |
Dasatinib sók
|
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
CA2965157A1
(en)
|
2014-11-25 |
2016-06-02 |
Nanocopoeia, Llc |
Method of converting a crystalline compound to an amorphous compound, method of increasing the solubility of a crystalline compound in a biorelevant fluid, and nanoparticles that achieve supersaturation
|
|
WO2016097011A1
(en)
|
2014-12-19 |
2016-06-23 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous nilotinib
|
|
US20160175881A1
(en)
|
2014-12-22 |
2016-06-23 |
Nanocopoeia, Llc |
Electrospray methods, electrospray systems, and methods of forming crystalline particles
|
|
JP6513702B2
(ja)
|
2014-12-25 |
2019-05-15 |
株式会社ダイセル |
超速崩壊錠剤及びその製造方法
|
|
WO2016118515A1
(en)
|
2015-01-20 |
2016-07-28 |
Handa Pharmaceuticals, Llc |
Stable solid fingolimod dosage forms
|
|
PT108368B
(pt)
|
2015-03-31 |
2018-11-05 |
Hovione Farm S A |
Produção contínua de partículas
|
|
JP2018517734A
(ja)
|
2015-06-17 |
2018-07-05 |
ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー |
デフェラシロクスの改善された製剤およびその作製方法
|
|
BR112017013253A2
(pt)
|
2015-07-27 |
2018-02-27 |
Unichem Laboratories Limited |
comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes
|
|
WO2017064538A1
(en)
|
2015-10-16 |
2017-04-20 |
Nobel Ilac Sanayii Ve Ticaret A.S. |
Pharmaceutical compositions of nilotinib hydrochloride
|
|
WO2017108605A1
(en)
|
2015-12-22 |
2017-06-29 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous dasatinib
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
WO2018078392A1
(en)
|
2016-10-29 |
2018-05-03 |
Cipla Limited |
Polymorphs of dasatinib
|
|
EP3705118B1
(en)
|
2017-10-31 |
2024-02-14 |
Samyang Holdings Corporation |
Oral solid dosage form composition having improved disintegration and preparation method therefor
|
|
WO2019151405A1
(ja)
|
2018-02-02 |
2019-08-08 |
ニプロ株式会社 |
錠剤及びその製造方法
|
|
TWI787523B
(zh)
|
2018-06-15 |
2022-12-21 |
漢達生技醫藥股份有限公司 |
達沙替尼十二烷基硫酸鹽之結晶
|
|
ES2993251T3
(en)
*
|
2019-02-18 |
2024-12-26 |
Slayback Pharma Llc |
Pharmaceutical compositions of nilotinib
|
|
IL295007A
(en)
|
2020-01-31 |
2022-09-01 |
Nanocopoeia Llc |
Amorphous nilotinib microparticles and uses thereof
|
|
US20230058417A1
(en)
*
|
2020-02-06 |
2023-02-23 |
Briggs & Stratton, Llc |
Battery pack for battery powered equipment
|
|
US20220378788A1
(en)
|
2020-04-30 |
2022-12-01 |
Nanocopoeia, Llc |
Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
|
|
WO2021222739A1
(en)
|
2020-04-30 |
2021-11-04 |
Nanocopoeia, Llc |
Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
|